FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055149575> ?p ?o ?g. }

• W2055149575 endingPage "435" @default.
• W2055149575 startingPage "435" @default.
• W2055149575 abstract "Safety and effectiveness of controlled-release paroxetine in routine clinical practice: results of a postmarketing surveillance study of patients with depression Masaki Kato,1 Toshifumi Kimura,2 Takeshi Kimura,3 Terufumi Hara3 1Department of Neuropsychiatry, Kansai Medical University, Moriguchi-shi, Osaka, Japan; 2Medical Affairs, 3Clinical Safety and PMS, Development and Medical Affairs Division, GlaxoSmithKline K.K., Shibuya-ku, Tokyo, Japan Objective: Selective serotonin reuptake inhibitors are commonly used in the pharmacotherapy of depression. However, adverse events can lead to their early discontinuation. This study evaluated the safety and effectiveness of paroxetine controlled-release (CR) tablets in Japanese patients with depression/depressive state (hereafter referred to as depression) in routine clinical practice in Japan. Patients and methods: This was an open-label, noninterventional, prospective, postmarketing surveillance study. A total of 3,213 patients aged 12–92 years with depression were prescribed paroxetine CR for 8 weeks at the physician’s discretion. Safety was evaluated on the basis of the reporting of adverse drug reactions. Effectiveness was evaluated on the basis of the physician’s assessment using the Clinical Global Impression-Global Improvement (CGI-GI) and the Clinical Global Impression-Severity of Illness (CGI-SI) scales, as well as on the basis of the patients’ self-reported satisfaction. The primary effectiveness outcome was the improvement rate based on the physician’s assessment using the CGI-GI. Results: The incidence of adverse drug reactions was 11.2% (359/3,213; 95% confidence interval [CI]: 10.1%–12.3%). The common adverse drug reactions that accounted for 1.0% or more of the incidence were nausea (3.5%) and somnolence (2.7%). The proportion of patients who continued paroxetine CR at week 8 was 80.2% (2,577/3,213; 95% CI: 78.8%–81.6%). The improvement rate at week 8 (last observation carried forward) was 72.8% (2,132/2,927; 95% CI: 71.2%–74.4%). The proportion of patients with CGI-SI scores of moderately or severely ill decreased from 63.6% at baseline to 17.9% at week 8. The proportion of patients who were satisfied with paroxetine CR treatment was 69.8% (2,040/2,921; 95% CI: 68.1%–71.5%). Conclusion: The results of this study suggest that paroxetine CR is a well-tolerated and efficacious treatment for depression in routine clinical practice. Keywords: paroxetine, controlled-release, postmarketing surveillance, depression" @default.
• W2055149575 created "2016-06-24" @default.
• W2055149575 creator A5032388871 @default.
• W2055149575 creator A5032624282 @default.
• W2055149575 creator A5062615598 @default.
• W2055149575 creator A5085128848 @default.
• W2055149575 date "2015-02-01" @default.
• W2055149575 modified "2023-09-23" @default.
• W2055149575 title "Safety and effectiveness of controlled-release paroxetine in routine clinical practice: results of&nbsp;a&nbsp;postmarketing surveillance study of patients with depression" @default.
• W2055149575 cites W1969114959 @default.
• W2055149575 cites W1982479536 @default.
• W2055149575 cites W1982892378 @default.
• W2055149575 cites W1994765909 @default.
• W2055149575 cites W1997010275 @default.
• W2055149575 cites W2007133771 @default.
• W2055149575 cites W2016362182 @default.
• W2055149575 cites W2022287986 @default.
• W2055149575 cites W2025500778 @default.
• W2055149575 cites W2046293215 @default.
• W2055149575 cites W2069638745 @default.
• W2055149575 cites W2085769789 @default.
• W2055149575 cites W2090432427 @default.
• W2055149575 cites W2105567689 @default.
• W2055149575 cites W2140746866 @default.
• W2055149575 cites W2149435665 @default.
• W2055149575 cites W2161024131 @default.
• W2055149575 cites W2333551401 @default.
• W2055149575 cites W2419123664 @default.
• W2055149575 cites W2917243324 @default.
• W2055149575 cites W63710928 @default.
• W2055149575 doi "https://doi.org/10.2147/ndt.s77542" @default.
• W2055149575 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4345990" @default.
• W2055149575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25759586" @default.
• W2055149575 hasPublicationYear "2015" @default.
• W2055149575 type Work @default.
• W2055149575 sameAs 2055149575 @default.
• W2055149575 citedByCount "3" @default.
• W2055149575 countsByYear W20551495752017 @default.
• W2055149575 countsByYear W20551495752018 @default.
• W2055149575 countsByYear W20551495752022 @default.
• W2055149575 crossrefType "journal-article" @default.
• W2055149575 hasAuthorship W2055149575A5032388871 @default.
• W2055149575 hasAuthorship W2055149575A5032624282 @default.
• W2055149575 hasAuthorship W2055149575A5062615598 @default.
• W2055149575 hasAuthorship W2055149575A5085128848 @default.
• W2055149575 hasBestOaLocation W20551495751 @default.
• W2055149575 hasConcept C118552586 @default.
• W2055149575 hasConcept C126322002 @default.
• W2055149575 hasConcept C139719470 @default.
• W2055149575 hasConcept C142724271 @default.
• W2055149575 hasConcept C162324750 @default.
• W2055149575 hasConcept C169900460 @default.
• W2055149575 hasConcept C197636746 @default.
• W2055149575 hasConcept C197934379 @default.
• W2055149575 hasConcept C204787440 @default.
• W2055149575 hasConcept C27081682 @default.
• W2055149575 hasConcept C2776000289 @default.
• W2055149575 hasConcept C2776867660 @default.
• W2055149575 hasConcept C2777828372 @default.
• W2055149575 hasConcept C2778715236 @default.
• W2055149575 hasConcept C2779177272 @default.
• W2055149575 hasConcept C2780051608 @default.
• W2055149575 hasConcept C558461103 @default.
• W2055149575 hasConcept C71924100 @default.
• W2055149575 hasConceptScore W2055149575C118552586 @default.
• W2055149575 hasConceptScore W2055149575C126322002 @default.
• W2055149575 hasConceptScore W2055149575C139719470 @default.
• W2055149575 hasConceptScore W2055149575C142724271 @default.
• W2055149575 hasConceptScore W2055149575C162324750 @default.
• W2055149575 hasConceptScore W2055149575C169900460 @default.
• W2055149575 hasConceptScore W2055149575C197636746 @default.
• W2055149575 hasConceptScore W2055149575C197934379 @default.
• W2055149575 hasConceptScore W2055149575C204787440 @default.
• W2055149575 hasConceptScore W2055149575C27081682 @default.
• W2055149575 hasConceptScore W2055149575C2776000289 @default.
• W2055149575 hasConceptScore W2055149575C2776867660 @default.
• W2055149575 hasConceptScore W2055149575C2777828372 @default.
• W2055149575 hasConceptScore W2055149575C2778715236 @default.
• W2055149575 hasConceptScore W2055149575C2779177272 @default.
• W2055149575 hasConceptScore W2055149575C2780051608 @default.
• W2055149575 hasConceptScore W2055149575C558461103 @default.
• W2055149575 hasConceptScore W2055149575C71924100 @default.
• W2055149575 hasLocation W20551495751 @default.
• W2055149575 hasLocation W20551495752 @default.
• W2055149575 hasLocation W20551495753 @default.
• W2055149575 hasLocation W20551495754 @default.
• W2055149575 hasOpenAccess W2055149575 @default.
• W2055149575 hasPrimaryLocation W20551495751 @default.
• W2055149575 hasRelatedWork W17659181 @default.
• W2055149575 hasRelatedWork W1993377670 @default.
• W2055149575 hasRelatedWork W2034112753 @default.
• W2055149575 hasRelatedWork W2053043565 @default.
• W2055149575 hasRelatedWork W2242285634 @default.
• W2055149575 hasRelatedWork W2507606681 @default.
• W2055149575 hasRelatedWork W2606796665 @default.
• W2055149575 hasRelatedWork W2946745931 @default.
• W2055149575 hasRelatedWork W3159907377 @default.
• W2055149575 hasRelatedWork W4306722605 @default.

• next